Keros Therapeutics (KROS) EBT (2019 - 2026)
Keros Therapeutics' (KROS) quarterly EBT came in at -$25.0 million in Q4 2025, up 45.38% YoY from -$17.2 million in Q4 2024, and down 186.94% on a QoQ basis from -$8.7 million in Q3 2025.
Keros Therapeutics (KROS) EBT (2019 - 2026) Analysis & Trends
Keros Therapeutics (KROS) has 7 years of EBT data on file, last reported at -$25.0 million in Q4 2025.
- Quarterly EBT rose 45.38% year-over-year to -$25.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $91.9 million (up 149.13% YoY) and the FY2025 annual result came in at $91.9 million, up 149.13% from the prior year.
- EBT slipped to -$25.0 million in Q4 2025, from -$8.7 million in the prior quarter.
- In the past five years, EBT ranged from a high of $158.5 million in Q1 2025 to a low of -$91.4 million in Q2 2023.
- A 5-year average of -$25.5 million and a median of -$28.5 million in 2022 frame the typical range for EBT.
- Annual changes were most pronounced in 2022 — EBT plunged 501.46% — and 2025, when it surged 467.62%.
- Tracing KROS's EBT over 5 years: stood at -$4.9 million in 2021, then sank by 501.46% to -$29.7 million in 2022, then slumped by 53.36% to -$45.6 million in 2023, then slipped by 0.33% to -$45.7 million in 2024, then soared by 45.38% to -$25.0 million in 2025.
- The last three EBT figures came in at -$25.0 million (Q4 2025), -$8.7 million (Q3 2025), and -$32.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Keros Therapeutics | 217.21 Mn | -40.40 Mn | - | -28.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -28.71 Mn |
| Dec 31, 2025 | -24.98 Mn |
| Sep 30, 2025 | -8.70 Mn |
| Jun 30, 2025 | -32.92 Mn |
| Mar 31, 2025 | 158.49 Mn |
| Dec 31, 2024 | -45.73 Mn |
| Sep 30, 2024 | -52.96 Mn |
| Jun 30, 2024 | -45.26 Mn |
| Mar 31, 2024 | -43.11 Mn |
| Dec 31, 2023 | -45.58 Mn |
| Sep 30, 2023 | -76.88 Mn |
| Jun 30, 2023 | -91.44 Mn |
| Mar 31, 2023 | -39.37 Mn |
| Dec 31, 2022 | -29.72 Mn |
| Sep 30, 2022 | -23.51 Mn |
| Jun 30, 2022 | -27.27 Mn |
| Mar 31, 2022 | -24.19 Mn |
| Dec 31, 2021 | -4.94 Mn |
| Sep 30, 2021 | -20.34 Mn |
| Jun 30, 2021 | -15.62 Mn |